20 November 2025
Cancers | Feature Papers from the First Half of 2025 in the “Clinical Research of Cancer” Section
You are accessing a machine-readable page. In order to be human-readable, please install an RSS reader.
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications.
Feature papers are submitted upon individual invitation or recommendation by the scientific editors and must receive positive feedback from the reviewers.
Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to readers, or important in the respective research area. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.
Original Submission Date Received: .
As Cancers (ISSN: 2072-6694) is an open access journal, you have free and unlimited access to the full text of all articles. We welcome you to read our feature papers from the first half of 2025 in the Section “Clinical Research of Cancer”, which are listed below:
1. “Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)”
by Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos and Kaushal Parikh
Cancers 2025, 17(3), 353; https://doi.org/10.3390/cancers17030353
Available online: https://www.mdpi.com/2072-6694/17/3/353
2. “Robotic-Assisted Colon Cancer Surgery: Faster Recovery and Less Pain Compared to Laparoscopy in a Retrospective Propensity-Matched Study”
by Chun-Yu Lin, Yi-Chun Liu, Chou-Chen Chen, Ming-Cheng Chen, Teng-Yi Chiu, Yi-Lin Huang, Shih-Wei Chiang, Chang-Lin Lin, Ying-Jing Chen, Chen-Yan Lin et al.
Cancers 2025, 17(2), 243; https://doi.org/10.3390/cancers17020243
Available online: https://www.mdpi.com/2072-6694/17/2/243
3. “Phase II Study of Atezolizumab and Bevacizumab Combination Therapy for Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib”
by Takeshi Terashima, Hidenori Kido, Noboru Takata, Tomoyuki Hayashi, Akihiro Seki, Hidetoshi Nakagawa, Kouki Nio, Tadashi Toyama, Noriho Iida, Shinya Yamada et al.
Cancers 2025, 17(2), 278; https://doi.org/10.3390/cancers17020278
Available online: https://www.mdpi.com/2072-6694/17/2/278
4. “Gas Plasma Technology and Immunogenic Cell Death: Implications for Chordoma Treatment”
by Sander Bekeschus, Karl Roessler, Oliver Kepp and Eric Freund
Cancers 2025, 17(4), 681; https://doi.org/10.3390/cancers17040681
Available online: https://www.mdpi.com/2072-6694/17/4/681
5. “Impact of Class III Obesity (Morbid Obesity) on the Perioperative, Functional, and Oncological Outcomes of Robotic-Assisted Radical Prostatectomy“
by Abdel Rahman Jaber, Shady Saikali, Marcio Covas Moschovas, Ahmed Gamal, Ela Patel, Marco Sandri, Travis Rogers and Vipul Patel
Cancers 2025, 17(4), 709; https://doi.org/10.3390/cancers17040709
Available online: https://www.mdpi.com/2072-6694/17/4/709
6. “A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for Treatment”
by Kangwen Xiao, Kuangying Yang and Angela C. Hirbe
Cancers 2025, 17(2), 180; https://doi.org/10.3390/cancers17020180
Available online: https://www.mdpi.com/2072-6694/17/2/180
You can view and submit relevant papers to Cancers via https://www.mdpi.com/journal/cancers.
Cancers Editorial Office